Fig. 2

Chemoprotection of murine 32D cells following transgenic expression of MDR1 and CDD. 32D cells transduced with LV.SFFV.MDR1, LV.SFFV.CDD or LV.SFFV.GFP lentiviral vectors were treated with (a) daunorubicin (n = 3–11) or (b) Ara-C (n = 4–10) monotherapy. 32D cells genetically modified with two drug resistance genes either by co-transduction of LV.SFFV.MDR1 and LV.SFFV.CDD or by LV.SFFV.CDD.2A.MDR1 transduction as well as LV.SFFV.GFP transduced cells were treated with (c) daunorubicin (n = 3–11), (d) Ara-C (n = 4–11) monotherapy or (e) combined daunorubicin/Ara-C therapy (n = 3–12). Data are presented as mean ± SD; *p ≤ 0.05/**p ≤ 0.01 denote significant differences compared to untransduced control (calculated by ANOVA)